文献速递白血病

靶向鞘氨醇激酶1诱导急性髓系白血病中MCL1依赖性细胞死亡

Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
PubMed 文献 · Blood · 2016-12-12

该研究探讨鞘氨醇激酶1(SPHK1)在原发性急性髓系白血病(AML)中的作用及靶向策略。SPHK1在AML患者原始细胞中过表达并持续激活,靶向SPHK1可诱导caspase依赖性细胞死亡,对正常骨髓CD34+祖细胞影响极小。SPHK1抑制剂可减少原位AML患者来源异种移植瘤负荷并延长总生存,且与BH3模拟物协同诱导AML细胞死亡。

要点

  • SPHK1在原发性AML患者原始细胞中过表达并持续激活,而在正常单核细胞中不表达。
  • 靶向SPHK1诱导AML细胞系、原代AML患者原始细胞及分离的白血病祖细胞/干细胞caspase依赖性死亡。
  • SPHK1抑制剂减少原位AML患者来源异种移植瘤负荷并延长总生存,且与BH3模拟物协同诱导AML细胞死亡。

核心结论

  • SPHK1是治疗AML的真正治疗靶点。

研究设计与样本

  • 研究使用原发性AML患者原始细胞、AML细胞系、分离的AML患者白血病祖细胞/干细胞、健康供者骨髓CD34+祖细胞及原位AML患者来源异种移植模型。

主要发现

  • SPHK1在原发性AML患者原始细胞中过表达并持续激活,而在正常单核细胞中不表达。
  • 靶向SPHK1诱导AML细胞系、原代AML患者原始细胞及分离的AML患者白血病祖细胞/干细胞caspase依赖性细胞死亡,对健康供者正常骨髓CD34+祖细胞影响可忽略。
  • 给予SPHK1抑制剂可减少原位AML患者来源异种移植瘤负荷并延长总生存,且不影响小鼠造血。
  • SPHK1抑制与S1P受体2生存信号减少相关,导致促生存蛋白MCL1选择性下调。
  • BH3模拟物联合SPHK1抑制或S1P受体2拮抗可协同触发AML细胞死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is an aggressive malignancy where despite improvements in conventional chemotherapy and bone marrow transplantation, overall survival remains poor. Sphingosine kinase 1 (SPHK1) generates the bioactive lipid sphingosine 1-phosphate (S1P) and has established roles in tumor initiation, progression, and chemotherapy resistance in a wide range of cancers. The role and targeting of SPHK1 in primary AML, however, has not been previously investigated. Here we show that SPHK1 is overexpressed and constitutively activated in primary AML patient blasts but not in normal mononuclear cells. Subsequent targeting of SPHK1 induced caspase-dependent cell death in AML cell lines, primary AML patient blasts, and isolated AML patient leukemic progenitor/stem cells, with negligible effects on normal bone marrow CD34+ progenitors from healthy donors. Furthermore, administration of SPHK1 inhibitors to orthotopic AML patient-derived xenografts reduced tumor burden and prolonged overall survival without affecting murine hematopoiesis. SPHK1 inhibition was associated with reduced survival signaling from S1P receptor 2, resulting in selective downregulation of the prosurvival protein MCL1. Subsequent analysis showed that the combination of BH3 mimetics with either SPHK1 inhibition or S1P receptor 2 antagonism triggered synergistic AML cell death. These results support the notion that SPHK1 is a bona fide therapeutic target for the treatment of AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Powell JA, Lewis AC, Zhu W, et al. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood. 2016. PMID: 27956387. doi:10.1182/blood-2016-06-720433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。